3 ms·

Newer and larger study: Thirty-Day Outcomes of Children and Adolescents With COVID-19: An International Experience https://publications.aap.org/pediatrics/arti

Newer and larger study: Thirty-Day Outcomes of Children and Adolescents With COVID-19: An International Experience https://publications.aap.org/pediatrics/article/148/3/e2020042929/179730/Thirty-Day-Outcomes-of-Children-and-Adolescents https://publications.aap.org/pediatrics/article/148/3/e20200... Is this truth? I really do not know.

Aachen 5y ago
Why not share the results rather than a link-only comment? > Dyspnea, bronchiolitis, anosmia, and gastrointestinal symptoms were more common in COVID-19 than influenza. In-hospital prevalent treatments for COVID-19 included repurposed medications (<10%) and adjunctive therapies: systemic corticosteroids (6.8%–7.6%), famotidine (9.0%–28.1%), and antithrombotics such as aspirin (2.0%–21.4%), heparin (2.2%–18.1%), and enoxaparin (2.8%–14.8%). Hospitalization was observed in 0.3% to 1.3% of the cohort diagnosed with COVID-19, with undetectable (n < 5 per database) 30-day fatality. Thirty-day outcomes including pneumonia and hypoxemia were more frequent in COVID-19 than influenza.